Document is current
Any future updates will be listed below
-
Authors
Lomholt, Søren https://orcid.org/0000-0001-5916-4219
Øllgaard, Ann Mai Brøndum Holm https://orcid.org/0009-0003-3114-0954
Madsen, Anni Aagaard
Nielsen, Morten Aagaard https://orcid.org/0000-0003-1077-9727
Kragstrup, Tue Wenzel https://orcid.org/0000-0002-6439-397X
-
Funding
Funding for this research was provided by:
Aarhus Universitet
- License Information
-
More Information
Article History
Received: 13 January 2026
Accepted: 17 March 2026
First Online: 5 May 2026
Declarations
:
: TWK: Speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, UCB, and AbbVie. Consultancy fees from Bristol-Myers Squibb, UCB, Gilead, and Eli-Lilly. Research grants from Gilead. Co-founder and clinical developer in Aptol Pharma.
: Primary human samples from patients with arthritis were obtained after informed consent, with approval from the regional ethical committee of Central Denmark (20121329) and in accordance with The Helsinki Declaration and Danish law.
